Humacyte, Inc. (HUMA) vs Pulmonx Corporation (LUNG)
A side-by-side comparison of Humacyte, Inc. and Pulmonx Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HUMA
Humacyte, Inc.
$0.51HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
LUNG
Pulmonx Corporation
$1.90HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — HUMA vs LUNG
growth of $100 · dividends reinvested · last 6yHUMA -94.8% (-39.0%/yr)LUNG -96.5% (-42.7%/yr)HUMA compounded faster over this window
HUMA LUNG
HUMA vs LUNG: by the numbers
- •HUMA is the larger company ($85M vs $80M market cap).
- •Both run net losses; LUNG's is the smaller (-55.03% vs -4560.82% net margin).
- •LUNG grew revenue faster over the past five years (15.86% vs 2.41% CAGR).
Metrics side by side
Valuation
| Metric | HUMA | LUNG |
|---|---|---|
| P/S ratio | 40.16 | 0.92 |
| P/B ratio | 2.72 | 2.04 |
Profitability
| Metric | HUMA | LUNG |
|---|---|---|
| Gross margin | -736.46% | 77.06% |
| Operating margin | -5271.69% | -52.96% |
| Net margin | -4560.82% | -55.03% |
| ROE | -309.44% | -122.76% |
| ROIC | -90.27% | -48.39% |
Growth (annualized)
| Metric | HUMA | LUNG |
|---|---|---|
| Revenue CAGR (5Y) | 2.41% | 15.86% |
| Total return CAGR (5Y) | -45.73% | -45.30% |
Frequently asked
- Which has grown faster, HUMA or LUNG?
- Over the past five years, LUNG grew revenue faster — HUMA at a 2.41% CAGR versus LUNG at 15.86%.
- How have HUMA and LUNG total returns compared?
- Over the past 5 years, HUMA delivered -45.73% and LUNG delivered -45.30% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Humacyte ROEPulmonx ROEHumacyte operating marginPulmonx operating marginHumacyte revenue growthPulmonx revenue growthHumacyte free cash flowPulmonx free cash flow
Humacyte & Pulmonx appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.